Activity Chair:
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA
Planning Committee and Faculty:
Marc P. Bonaca, MD, MPH
Investigator TIMI Study Group
Vascular Medicine Section, Cardiovascular Division
Brigham and Women’s Hospital Heart & Vascular Center
Boston, MA
David A. Morrow, MD, MPH
Director, Samuel A. Levine Cardiac Unit
Professor of Medicine
Harvard Medical School, Brigham & Woman's Hospital
Boston, MA
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
Associate Director Duke Heart Center – Cardiology Clinics
Director, Program for Advanced Coronary Disease
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC
Reviewers:
David Davidson, MD
Ronald Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 1/11/2018)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
Activity Chair and Faculty member reports the following relationship(s) which are accurate at the time of original content release (2/24/2016):
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi-Aventis, The Medicines Company
Marc P. Bonaca, MD, MPH
Consulting Fee: AstraZeneca, Bayer, Merck
David A. Morrow, MD, MPH
Consulting Fee: diaDexus, Eli Lilly, Gilead, Merck, Novartis, Radiometer
Research Funding (paid to institution): Abbott Diagnostics, Amgen, AstraZeneca, Anthera, Beckman Coulter, BG Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Eisai, GlaxoSmithKline, Johnson & Johnson, Merck, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Randox, Roche Diagnostics, Sanofi-Aventis, Siemens, Singulex
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Consulting Fee: Abiomed, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals, Stealth Peptides, The Medicines Company, WebMD
Contracted Research (paid to institution): Bayer, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals
Reviewers report the following relationship(s):
David Davidson, MD
Consulting Fee: Sanofi/Regeneron
Contracted Research: Astra Zeneca, Bayer, Pfizer
Ronald Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.